New York, USA – April 12, 2024 – Neurodegenerative diseases pose a significant challenge to modern medicine, with conditions such as Alzheimer’s, Parkinson’s, and Huntington’s diseases affecting millions worldwide. Traditional research methods often fall short of accurately recapitulating the complex cellular and molecular processes underlying these debilitating conditions. iPSCs serve as a powerful tool for both drug discovery and disease modeling, bringing a promising future in neurodegenerative disease modeling. With years of experience in this area, Creative Biolabs is confident to drive discoveries forward with its advanced development platform and innovative solutions.
“Brain organoids offer an effective means to various neurological diseases, offering advanced disease modeling capabilities, including complex conditions like Alzheimer’s and Parkinson’s, within a controlled environment,” stated a scientist at Creative Biolabs. “Organoids can be derived from adult stem cells obtained from tissue samples, or by guiding the differentiation of pluripotent stem cells.”
Creative Biolabs’ expertise in differentiating iPSCs offers a reliable and efficient solution for researchers and biotech companies seeking high-quality differentiated cells for brain organoid development services. With a team of professional scientists in iPSC differentiation and state-of-the-art platforms, Creative Biolabs is dedicated to offering custom brain organoid services, including forebrain organoids, cerebellar organoids, whole-brain organoids, and retinal organoids.
“Furthermore, we have established a cutting-edge STEMOD™ platform to assist researchers in stem cell-based drug discovery and development, delivering appropriate solutions to meet their research needs in disease modeling,” added the senior scientist.
Creative Biolabs offers a comprehensive range of STEMOD™ based services to accelerate research progress in neurological diseases, including:
* STEMOD™ based drug discovery: enabling direct assessment of the effects, side effects, and toxicity from multiple perspectives.
* STEMOD™ based high content screening: advancing research across various scientific research areas, including neurology, immuno-oncology, toxicology, and stem cell research.
* STEMOD™ iPSC-derived neurogenerative disease models: providing a platform to explore disease mechanisms in these conditions.
For further details about services for neurodegenerative disease research services at Creative Biolabs, please visit https://www.creative-biolabs.com/stem-cell-therapy.
About Creative Biolabs
Creative Biolabs remains committed to collaborating with academic institutions, pharmaceutical partners, and regulatory authorities to further neurodegenerative disease research. Leveraging its cutting-edge development platform and technologies, the company is dedicated to unlocking the complexities of the brain, ushering in a new era in the study of neurodegenerative diseases.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/stem-cell-therapy